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Preoperative imaging for colorectal liver metastases: a
nationwide population-based study
A. K. E. Elfrink1,3 , M. Pool4,6, L. R. van der Werf1,8, E. Marra1, M. C. Burgmans2, M. R. Meijerink5,
M. den Dulk9, P. B. van den Boezem10, W. W. te Riele11,16, G. A. Patijn12, M. W. J. M. Wouters1, W.
K. G. Leclercq13, M. S. L. Liem14, P. D. Gobardhan15, C. I. Buis3, K. F. D. Kuhlmann7, C. Verhoef8,
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Background: In patients with colorectal liver metastases (CRLM) preoperative imaging may include
contrast-enhanced (ce) MRI and [18F]fluorodeoxyglucose (18F-FDG) PET–CT. This study assessed
trends and variation between hospitals and oncological networks in the use of preoperative imaging in
the Netherlands.
Methods: Data for all patients who underwent liver resection for CRLM in the Netherlands between
2014 and 2018 were retrieved from a nationwide auditing database. Multivariable logistic regression
analysis was used to assess use of ceMRI, 18F-FDG PET–CT and combined ceMRI and 18F-FDG
PET–CT, and trends in preoperative imaging and hospital and oncological network variation.
Results: A total of 4510 patients were included, of whom 1562 had ceMRI, 872 had 18F-FDG PET–CT,
and 1293 had combined ceMRI and 18F-FDG PET–CT. Use of ceMRI increased over time (from 9⋅6
to 26⋅2 per cent; P < 0⋅001), use of 18F-FDG PET–CT decreased (from 28⋅6 to 6⋅0 per cent; P < 0⋅001),
and use of both ceMRI and 18F-FDG PET–CT 16⋅9 per cent) remained stable. Unadjusted variation in
the use of ceMRI, 18F-FDG PET–CT, and combined ceMRI and 18F-FDG PET–CT ranged from 5⋅6
to 100 per cent between hospitals. After case-mix correction, hospital and oncological network variation
was found for all imaging modalities.
Discussion: Significant variation exists concerning the use of preoperative imaging for CRLM between
hospitals and oncological networks in the Netherlands. The use of MRI is increasing, whereas that of
18F-FDG PET–CT is decreasing.
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Introduction
Colorectal liver metastases (CRLM) are the leading indi-
cation for liver surgery in the Netherlands, accounting for
approximately 1000 liver resections each year1.
Current multidisciplinary management of CRLM by
surgeons, interventional radiologists, radiation therapists
and oncologists demands detailed preoperative knowl-
edge consisting of anatomical location in relation to
vascular structures, number and size of CRLM, and
individual patients’ risks and preferences2,3. Increasingly
used options include contrast-enhanced (ce) MRI and
[18F]fluorodeoxyglucose (18F-FDG) PET–CT4–6. ceMRI
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Table 1 Baseline characteristics for preoperative imaging in patients diagnosed with colorectal liver metastases between 2014 and








(n = 1293) P‡
Age (years) 0⋅038
≤70 496 (63⋅5) 1001 (64⋅2) 520 (59⋅7) 867 (67⋅2)
>70 285 (36⋅5) 559 (35⋅8) 351 (40⋅3) 424 (32⋅8)
Missing 2 2 1 2
Sex 0⋅078
M 468 (59⋅8) 1012 (64⋅8) 555 (63⋅6) 796 (61⋅6)
F 315 (40⋅2) 550 (35⋅2) 317 (36⋅4) 497 (38⋅4)
Charlson Co-morbidity Index <0⋅001
0–1 593 (76⋅7) 1186 (77⋅1) 598 (69⋅0) 955 (74⋅7)
≥2 180 (23⋅3) 352 (22⋅9) 269 (31⋅0) 324 (25⋅3)
Missing 10 24 5 14
BMI (kg/m2)* 26⋅1(4⋅4) 26⋅3(4⋅3) 26⋅1(4⋅4) 26⋅5(4⋅4) 0⋅124§
ASA grade 0⋅032
I–II 606 (77⋅9) 1271 (81⋅6) 654 (79⋅3) 1058 (82⋅6)
≥ III 172 (22⋅1) 286 (18⋅4) 171 (20⋅7) 223 (17⋅4)
Missing 5 5 47 12
Previous liver resection 0⋅002
No 615 (79⋅8) 1303 (84⋅6) 681 (79⋅0) 1063 (82⋅7)
Yes 156 (20⋅2) 238 (15⋅4) 181 (21⋅0) 222 (17⋅3)
Missing 12 21 10 8
History of liver disease† 0⋅145
No 758 (98⋅8) 1499 (98⋅1) 839 (98⋅5) 1225 (99⋅1)
Yes 9 (1⋅2) 29 (1⋅9) 13 (1⋅5) 11 (0⋅9)
Missing 16 34 20 57
History of preoperative chemotherapy <0⋅001
No 457 (64⋅5) 1004 (70⋅1) 581 (75⋅0) 800 (68⋅6)
Yes 252 (35⋅5) 429 (29⋅9) 194 (25⋅0) 367 (31⋅4)
Missing 74 129 97 126
No. of lesions <0⋅001
1 353 (47⋅5) 617 (40⋅5) 440 (52⋅1) 515 (40⋅8)
2 153 (20⋅6) 339 (22⋅3) 199 (23⋅6) 260 (20⋅6)
3 91 (12⋅2) 160 (10⋅5) 95 (11⋅3) 157 (12⋅5)
4 52 (7⋅0) 112 (7⋅4) 41 (4⋅9) 110 (8⋅7)
5 28 (3⋅8) 81 (5⋅3) 24 (2⋅8) 57 (4⋅5)
>5 66 (8⋅9) 214 (14⋅1) 45 (5⋅3) 162 (12⋅8)
Missing 40 39 28 32
Maximum diameter of largest CRLM (mm) <0⋅001
<20 169 (26⋅2) 514 (35⋅8) 180 (24⋅7) 369 (31⋅3)
20–34 232 (36⋅0) 544 (37⋅9) 297 (40⋅8) 437 (37⋅1)
35–54 137 (21⋅3) 239 (16⋅7) 157 (21⋅6) 231 (19⋅6)
≥55 106 (16⋅5) 137 (9⋅6) 94 (12⋅9) 141 (12⋅0)
Missing 139 128 144 115
Location of primary tumour <0⋅001
Colon 527 (67⋅5) 974 (62⋅5) 614 (70⋅4) 793 (61⋅3)
Rectum 254 (32⋅5) 584 (37⋅5) 258 (29⋅6) 500 (38⋅7)
Missing 2 4 0 0
Nodal status of primary tumour 0⋅109
pN0 194 (35⋅6) 405 (37⋅0) 281 (41⋅4) 366 (37⋅3)
pN1 206 (37⋅8) 406 (37⋅1) 233 (34⋅3) 349 (35⋅5)
pN2 145 (26⋅6) 284 (25⋅9) 165 (24⋅3) 267 (27⋅2)
Unknown 238 467 193 311
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 605–621
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(n = 1293) P‡
Type of metastases <0⋅001
Metachronous 390 (50⋅4) 723 (46⋅6) 552 (63⋅9) 697 (54⋅6)
Synchronous 384 (49⋅6) 827 (53⋅4) 312 (36⋅1) 580 (45⋅4)
Missing 9 12 8 16
Extrahepatic disease <0⋅001
No 628 (91⋅1) 1383 (93.8) 702 (88.5) 1110 (91.1)
Yes 61 (8.9) 92 (6.2) 91 (11.5) 109 (8.9)
Missing 94 87 79 74
Type of hospital <0⋅001
Regional 350 (44⋅7) 928 (59⋅4) 499 (57⋅2) 713 (55⋅1)
Tertiary referral centre 433 (55⋅3) 634 (40⋅6) 373 (42⋅8) 580 (44⋅9)
Year of surgery <0⋅001
2014 178 (22⋅7) 150 (9⋅6) 249 (28⋅6) 194 (15⋅0)
2015 142 (18⋅1) 250 (16⋅0) 219 (25⋅1) 273 (21⋅1)
2016 155 (19⋅8) 340 (21⋅8) 224 (25⋅7) 289 (22⋅4)
2017 150 (19⋅2) 413 (26⋅4) 128 (14⋅7) 318 (24⋅6)
2018 158 (20⋅2) 409 (26⋅2) 52 (6⋅0) 219 (16⋅9)
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). †Liver cirrhosis, oesophageal variceal disease, hepatorenal
syndrome, liver failure, alcoholic liver disease, toxic liver disease (mild), (chronic) hepatitis or liver fibrosis. CRLM, colorectal liver metastases. ‡χ2 test or
Fisher’s exact test, except §independent two-samples t test.
has been suggested to have a significant advantage over
CT in detecting additional (small) liver metastases, in
particular those of subcapsular or peribiliary origin4,7–11.
The oncological advantage of preoperative 18F-FDG
PET–CT to assess CRLM is doubtful12, although this
imaging method seems to have an advantage in iden-
tifying extrahepatic metastases of colorectal cancer13.
Some authors14,15 propose using 18F-FDG PET–CT
during follow-up to assess intrahepatic and extrahepatic
metastases. Several European countries have preoperative
imaging guidelines that contain advice regarding the use
of both ceMRI and 18F-FDG PET–CT16. Guidelines in
the UK17,18 and Japan19, as well as the European Society
for Medical Oncology consensus guideline on metastatic
colorectal cancer20, point out that ceMRI and 18F-FDG
PET–CT can be performed in the preoperative work-up.
However, these guidelines indicate that more research is
needed to address the added value of preoperative imaging
in patients with CRLM.
The Dutch guidelines21 in dicate that, at baseline, CT
should be performed to assess the presence of CRLM22.
If treatment is considered, ceMRI can be performed to
detect lesions smaller than 10 mm. The guideline further
states that 18F-FDG PET–CT should not be performed
as part of preoperative work-up, but is indicated only when
extrahepatic metastases are suspected.
The aims of the present study were to provide a
population-based overview of factors associated with
the use of different types of preoperative imaging modal-
ity, in patients with colorectal liver metastases, to report
on trends over the years, and to assess variation between
hospitals and oncological networks in the Netherlands.
Methods
This was a population-based nationwide cohort study
performed in the Netherlands with data from the Dutch
Hepato-Biliary Audit (DHBA)23. The Netherlands is a
western European country with approximately 17 mil-
lion inhabitants living on 33 883 square kilometres24.
Healthcare is organized in 71 hospitals, including seven
university hospitals and one comprehensive cancer
centre23,25. Twenty-five hospitals perform liver surgery.
A national minimum annual centre volume of 20 liver
resections and infrastructural requirements (24/7 avail-
ability of an interventional radiologist) have led to the
centralization of liver surgery26. Hospitals perform-
ing liver surgery in the Netherlands have been obliged
to register liver resections in the DHBA since 2013.
Detailed information on patient and disease character-
istics, as well as diagnostic and treatment information,
has been collected from 2013 onwards. Information
regarding the formation and content of the DHBA
has been described previously23. Data verification pro-
vided insight into the completeness and accuracy of the
DHBA27. During this process, data in the DHBA were
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 605–621
BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd
608 A. K. E. Elfrink, M. Pool, L. R. van der Werf, E. Marra, M. C. Burgmans, M. R. Meijerink et al.
Table 2 Association model of patient and tumour factors with the use of preoperative contrast-enhanced MRI in patients with
colorectal liver metastases in the Netherlands, 2014–2018
Univariable analysis* Multivariable analysis*
No. of patients
(n = 4510) Odds ratio P Adjusted odds ratio P
Age (years) 0⋅015 0⋅632
≤50 315 1⋅00 (reference) 1⋅00 (reference)
50–64 1543 0⋅93 (0⋅72, 1⋅21) 0⋅603 0⋅96 (0⋅50, 1⋅96) 0⋅762
65–79 2331 0⋅81 (0⋅63, 1⋅04) 0⋅097 0⋅88 (0⋅71, 1⋅28) 0⋅383
≥80 314 0⋅67 (0⋅48, 0⋅93) 0⋅016 0⋅86 (0⋅66, 1⋅17) 0⋅418
Missing† 7
Sex 0⋅310
M 2831 1⋅00 (reference)
F 1679 0⋅94 (0⋅83, 1⋅06)
Charlson Co-morbidity Index 0⋅012 0⋅753
0–1 3332 1⋅00 (reference) 1⋅00 (reference)
≥2 1125 0⋅84 (0⋅73, 0⋅96) 0⋅98 (0⋅83, 1⋅14)
Missing† 53
BMI 1⋅02 (1⋅00, 1⋅04) 0⋅023 1⋅02 (1⋅01, 1⋅04) 0⋅014
ASA grade 0⋅005 0⋅001
I–II 3589 1⋅00 (reference) 1⋅00 (reference)
≥ III 852 0⋅80 (0⋅69, 0⋅94) 0⋅74 (0⋅62, 0⋅88)
Missing† 69
History of liver disease‡ 0⋅811
No 4321 1⋅00 (reference)
Yes 62 1⋅07 (0⋅64, 1⋅83)
Missing† 127
History of liver resection <0⋅001 0⋅006
No 3662 1⋅00 (reference) 1⋅00 (reference)
Yes 797 0⋅75 (0⋅64, 0⋅87) 0⋅79 (0⋅66, 0⋅94)
Missing† 51
History of preoperative chemotherapy 0⋅708
No 2842 1⋅00 (reference)
Yes 1242 1⋅03 (0⋅89, 1⋅18)
Missing† 426
No. of CRLM <0⋅001 < 0⋅001
1 1925 1⋅00 (reference) 1⋅00 (reference)
2 951 1⋅19 (1⋅02, 1⋅40) 0⋅031 1⋅19 (1⋅00, 1⋅42) 0⋅051
3 503 1⋅19 (0⋅98, 1⋅46) 0⋅086 1⋅28 (1⋅02, 1⋅60) 0⋅047
4 315 1⋅67 (1⋅30, 2⋅17) <0⋅001 1⋅71 (1⋅29, 2⋅27) 0⋅001
5 190 1⋅86 (1⋅34, 2⋅61) <0⋅001 1⋅86 (1⋅29, 2⋅69) 0⋅002
>5 487 2⋅37 (1⋅89, 3⋅00) <0⋅001 2⋅45 (1⋅89, 3⋅17) <0⋅001
Missing† 139
Maximum diameter of largest CRLM (mm) <0⋅001 < 0⋅001
<20 1232 1⋅00 (reference) 1⋅00 (reference)
20–34 1510 0⋅73 (0⋅62, 0⋅86) <0⋅001 0⋅72 (0⋅61, 0⋅87) < 0⋅001
35–54 764 0⋅63 (0⋅52, 0⋅77) <0⋅001 0⋅66 (0⋅53, 0⋅81) < 0⋅001
≥55 478 0⋅55 (0⋅44, 0⋅69) <0⋅001 0⋅56 (0⋅44, 0⋅72) < 0⋅001
Missing 526 0⋅34 (0⋅27, 0⋅42) <0⋅001 0⋅32 (0⋅25, 0⋅40) < 0⋅001
Bilobar disease 0⋅716
No 2423 1⋅00 (reference)
Yes 2043 1⋅02 (0⋅91, 1⋅16)
Missing† 44
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 605–621
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Table 2 Continued
Univariable analysis* Multivariable analysis*
No. of patients
(n = 4510) Odds ratio P Adjusted odds ratio P
Location of primary tumour <0⋅001 <0⋅001
Colon 2908 1⋅00 (reference) 1⋅00 (reference)
Rectal 1596 1⋅37 (1⋅20, 1⋅56) 1⋅44 (1⋅25, 1⋅67)
Missing† 6
Nodal stage of primary tumour 0⋅607
pN0 1246 1⋅00 (reference)
pN1 1194 1⋅06 (0⋅90, 1⋅25) 0⋅489
pN2 861 1⋅10 (0⋅91, 1⋅31) 0⋅323
Missing 1209 1⋅11 (0⋅94, 1⋅31) 0⋅204
Type of metastases <0⋅001 0⋅012
Metachronous 2362 1⋅00 (reference) 1⋅00 (reference)
Synchronous 2103 1⋅34 (1⋅19, 1⋅52) 1⋅22 (1⋅05, 1⋅41)
Missing† 45
Extrahepatic metastases <0⋅001 0⋅003
No 3823 1⋅00 (reference) 1⋅00 (reference)
Yes 566 0⋅66 (0⋅56, 0⋅80) 0⋅74 (0⋅60, 0⋅90)
Missing 121
Type of hospital <0⋅001 <0⋅001
Regional 2490 1⋅00 (reference) 1⋅00 (reference)
Tertiary referral centre§ 2020 0⋅78 (0⋅69, 0⋅88) 0⋅79 (0⋅66, 0⋅89)
Values in parentheses are 95 per cent confidence intervals. *Multilevel logistic regression model with individuals nested for year of surgery. †Missing values
not included in analyses because of relatively small group. ‡Liver cirrhosis, oesophageal variceal disease, hepatorenal syndrome, liver failure, alcoholic liver
disease, toxic liver disease (mild), (chronic) hepatitis or liver fibrosis. §Defined as hospitals with highest expertise on oncological surgery.
compared with those in the Dutch Cancer Registry.
The completeness of data retrieved from 2015 was 97
per cent23.
Patient selection
All consecutive patients who underwent liver resection for
CRLM between 1 January 2014 and 31 December 2018,
and were registered in the DHBA before 22 March 2019,
were included in the study. Patients who had ablation of
CRLM alone were not included in the study as registration
of such patients in the DHBA commenced on 1 January
2018. Patients were considered not eligible for analysis
when missing data included date of birth, preoperative
imaging modalities used, date of surgery, type of procedure
or origin of the tumour for which resection was performed.
No ethical approval was needed as the DHBA is an
obligatory audit from the Dutch inspectorate of healthcare
and all analyses were performed on an anonymized data set.
Patient groups
In all patients CT of the abdomen and chest was per-
formed as baseline imaging. Patients were divided into
four groups for analysis: no additional imaging of the liver;
preoperative imaging consisting of CT and ceMRI of the
liver; preoperative imaging consisting of CT and 18F-FDG
PET–CT; and preoperative imaging consisting of CT,
ceMRI and 18F-FDG PET–CT.
Variables
Studied variables included patient characteristics (age, sex,
ASA fitness grade, co-morbidity score according to the
Charlson Co-morbidity Index (CCI), liver disease before
surgery, previous liver surgery for CRLM and year of
surgery), tumour characteristics (number of CRLM, dia-
meter of largest CRLM before treatment on preoperative
CT, synchronous or metachronous metastases, presence
of extrahepatic metastases, and whether metastases were
bilobar), and type of hospital and oncological network
where treatment took place. Factors contributing to the
use of ceMRI, 18F-FDG PET–CT, and combined use
of ceMRI and 18F-FDG PET–CT were primary vari-
ables for case-mix correction. Other studied variables and
parameters were the use of the different preoperative
imaging modalities over the years, and between-hospital
and between-oncological network variation in the use of
preoperative imaging modalities. Both were corrected for
case-mix variables.
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 605–621
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Table 3 Association model of patient and tumour factors with the use of preoperative [18F]fluorodeoxyglucose PET–CT in patients with
colorectal liver metastases in the Netherlands, 2014–2018
Univariable analysis* Multivariable analysis*
No. of patients
(n = 4510) Odds ratio P Adjusted odds ratio P
Age (years) 0⋅314
≤50 315 1⋅00 (reference)
50–64 1543 1⋅13 (0⋅88, 1⋅44) 0⋅333
65–79 2331 1⋅22 (0⋅97, 1⋅55) 0⋅096
≥80 314 1⋅17 (0⋅86, 1⋅61) 0⋅319
Missing† 7
Sex 0⋅622
M 2831 1⋅00 (reference)
F 1679 1⋅03 (0⋅91, 1⋅16)
Charlson Co-morbidity Index <0⋅001 0⋅003
0–1 3332 1⋅00 (reference) 1⋅00 (reference)
≥2 1125 1⋅28 (1⋅12, 1⋅46) 1⋅22 (1⋅05, 1⋅40)
Missing† 53
BMI 1⋅00 (0⋅99, 1⋅02) 0⋅815
ASA grade 0⋅444
I–II 3589 1⋅00 (reference)
≥ III 852 0⋅94 (0⋅81, 1⋅10)
Missing† 69
History of liver disease‡ 0⋅156
No 4321 1⋅00 (reference)
Yes 62 0⋅69 (0⋅41, 1⋅15)
Missing† 127
History of liver resection 0⋅132
No 3662 1⋅00 (reference)
Yes 797 1⋅12 (0⋅97, 1⋅31)
Missing† 51
History of preoperative chemotherapy 0⋅044 0⋅164
No 2842 1⋅00 (reference) 1⋅00 (reference)
Yes 1242 0⋅87 (0⋅77, 1⋅00) 0⋅97 (0⋅94, 1⋅32)
Missing† 426
No. of CRLM 0⋅056 0⋅235
1 1925 1⋅00 (reference) 1⋅00 (reference)
2 951 0⋅95 (0⋅81, 1⋅11) 0⋅498 0⋅89 (0⋅75, 1⋅06) 0⋅170
3 503 1⋅02 (0⋅84, 1⋅24) 0⋅845 1⋅04 (0⋅85, 1⋅34) 0⋅786
4 315 0⋅94 (0⋅74, 1⋅19) 0⋅582 0⋅96 (0⋅73, 1⋅26) 0⋅561
5 190 0⋅75 (0⋅56, 1⋅02) 0⋅067 0⋅80 (0⋅57, 1⋅12) 0⋅206
>5 487 0⋅75 (0⋅61, 0⋅92) 0⋅005 0⋅81 (0⋅64, 1⋅04) 0⋅091
Missing† 139
Maximum diameter of largest CRLM (mm) 0⋅060 0⋅018
<20 1232 1⋅00 (reference) 1⋅00 (reference)
20–34 1510 1⋅17 (1⋅02, 1⋅37) 0⋅035 1⋅18 (1⋅01, 1⋅39) 0⋅034
35–54 764 1⋅28 (1⋅07, 1⋅54) 0⋅007 1⋅30 (1⋅08, 1⋅62) 0⋅002
≥55 478 1⋅20 (0⋅97, 1⋅49) 0⋅087 1⋅29 (1⋅03, 1⋅62) 0⋅027
Missing 526 1⋅21 (0⋅98, 1⋅48) 0⋅072 1⋅34 (1⋅06, 1⋅68) 0⋅009
Bilobar disease 0⋅041 0⋅096
No 2423 1⋅00 (reference) 1⋅00 (reference)
Yes 2043 1⋅13 (1⋅01, 1⋅27) 1⋅15 (0⋅97, 1⋅36)
Missing† 44
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 605–621
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Table 3 Continued
Univariable analysis* Multivariable analysis*
No. of patients
(n = 4510) Odds ratio P Adjusted odds ratio P
Location of primary tumour 0⋅567
Colon 2908 1⋅00 (reference)
Rectal 1596 0⋅96 (0⋅85, 1⋅09)
Missing† 6
Nodal stage of primary tumour <0⋅001 0⋅104
pN0 1246 1⋅00 (reference) 1⋅00 (reference)
pN1 1194 0⋅88 (0⋅75, 1⋅03) 0⋅117 0⋅89 (0⋅75, 1⋅05) 0⋅184
pN2 861 0⋅93 (0⋅78, 1⋅11) 0⋅429 0⋅96 (0⋅80, 0⋅96) 0⋅591
Missing 1209 0⋅66 (0⋅56, 0⋅78) <0⋅001 0⋅80 (0⋅67, 0⋅96) 0⋅024
Type of metastases <0⋅001 <0⋅001
Metachronous 2362 1⋅00 (reference) 1⋅00 (reference)
Synchronous 2103 0⋅66 (0⋅58, 0⋅74) 0⋅66 (0⋅58, 0⋅76)
Missing† 45
Extrahepatic metastases <0⋅001 <0⋅001
No 3823 1⋅00 (reference) 1⋅00 (reference)
Yes 566 1⋅44 (1⋅21, 1⋅73) 1⋅45 (1⋅20, 1⋅75)
Missing 121
Type of hospital 0⋅317
Regional 2490 1⋅00 (reference)
Tertiary referral centre§ 2020 0⋅94 (0⋅84, 1⋅06)
Values in parentheses are 95 per cent confidence intervals. *Multilevel logistic regression model with individuals nested for year of surgery. †Missing values
not included in analyses because of relatively small group. ‡Liver cirrhosis, oesophageal variceal disease, hepatorenal syndrome, liver failure, alcoholic liver
disease, toxic liver disease (mild), (chronic) hepatitis or liver fibrosis. §Defined as hospitals with highest expertise on oncological surgery.
All variables concerning tumour characteristics were
based on normal preoperative work-up before surgery, and
therefore assessed using preoperative CT before additional
imaging was performed. However, as a result of the retro-
spective nature of this study, these variables might resem-
ble characteristics of the CRLM after ceMRI or 18F-FDG
PET–CT. Sensitivity analyses were performed in all statis-
tical models, which consisted of dropping tumour charac-
teristics.
As described previously28, oncological networks were
classified according to treatment collaboration between
hospitals, or topographical location if no collaboration
network was present (Fig. S1, supporting information). An
oncological network consists of one or more tertiary refer-
ral centres, including one of the seven university hospitals
in the Netherlands. All regional hospitals are included
in an oncological network, of which a few perform liver
surgery. Regional hospitals not performing liver surgery
refer patients to either a regional hospital performing
liver surgery or tertiary referral centre for the treatment
of CRLM, based on agreements in the oncology net-
work. All hospitals in an oncological network have multi-
disciplinary meetings using video conferencing to discuss
patients with CRLM and obtain a patient-centred
treatment plan. If necessary, patients with a high surgical
risk as a result of co-morbidity or need for more complex
surgical procedures can be referred to tertiary referral
centres28.
Statistical analysis
Baseline characteristics were compared between all groups
using the χ2 test or Fisher’s exact test as appropriate for
categorical variables. Continuous variables were compared
using independent two-samples t test.
Identification of case-mix factors, defined as
non-modifiable patient and tumour characteristics influ-
encing the use of the different preoperative imaging
modalities, was performed. Potential case-mix factors
were entered in univariable and multivariable multilevel
logistic regression models, one model for each preoper-
ative imaging modality. A multilevel analysis was used to
take into account the changes in hospital policy, as well
as unmeasured similarities of patients within the year
of surgery. Separate analysis for trends in preoperative
imaging over the years was performed using univariable
and multivariable logistic regression for each treatment
modality. These models were performed using case-mix
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Table 4 Association model of patient and tumour factors with the use of preoperative contrast-enhanced MRI and
[18F]fluorodeoxyglucose PET–CT in patients with colorectal liver metastases in the Netherlands, 2014–2018
Univariable analysis* Multivariable analysis*
No. of patients
(n = 4510) Odds ratio P Adjusted odds ratio P
Age (years) 0⋅289
≤50 315 1⋅00 (reference)
50–64 1543 1⋅04 (0⋅80, 1⋅36) 0⋅802
65–79 2331 0⋅96 (0⋅74, 1⋅24) 0⋅730
≥80 314 0⋅80 (0⋅56, 1⋅14) 0⋅218
Missing† 7
Sex
M 2831 1⋅00 (reference)
F 1679 1⋅07 (0⋅94, 1⋅23)
Charlson Co-morbidity Index 0⋅929
0–1 3332 1⋅00 (reference)
≥2 1125 1⋅01 (0⋅87, 1⋅17)
Missing† 53
BMI 1⋅01 (1⋅00, 1⋅03) 0⋅091 1⋅01 (0⋅99, 1⋅04) 0⋅204
ASA grade 0⋅056 0⋅126
I–II 3589 1⋅00 (reference) 1⋅00 (reference)
≥ III 852 0⋅85 (0⋅72, 1⋅00) 0⋅87 (0⋅73, 1⋅04)
Missing† 69
History of liver disease‡ 0⋅057 0⋅057
No 4321 1⋅00 (reference) 1⋅00 (reference)
Yes 62 0⋅54 (0⋅27, 1⋅01) 0⋅51 (0⋅26, 1⋅02)
Missing† 127
History of liver resection 0⋅010 0⋅760
No 3662 1⋅00 (reference) 1⋅00 (reference)
Yes 797 0⋅75 (0⋅64, 0⋅87) 0⋅97 (0⋅81, 1⋅17)
Missing† 51
History of preoperative chemotherapy 0⋅324
No 2842 1⋅00 (reference)
Yes 1242 1⋅07 (0⋅93, 1⋅24)
Missing† 426
No. of CRLM 0⋅005 0⋅126
1 1925 1⋅00 (reference) 1⋅00 (reference)
2 951 1⋅03 (0⋅86, 1⋅23) 0⋅738 0⋅93 (0⋅76, 1⋅13) 0⋅467
3 503 1⋅24 (1⋅00, 1⋅54) 0⋅051 1⋅21 (0⋅95, 1⋅55) 0⋅129
4 315 1⋅47 (1⋅14, 1⋅89) 0⋅002 1⋅28 (0⋅95, 1⋅71) 0⋅099
5 190 1⋅17 (0⋅84, 1⋅62) 0⋅341 1⋅06 (0⋅74, 1⋅53) 0⋅752
>5 487 1⋅37 (1⋅10, 1⋅69) 0⋅004 1⋅22 (0⋅94, 1⋅58) 0⋅140
Missing† 139
Maximum diameter of largest CRLM (mm) 0⋅005 0⋅024
<20 1232 1⋅00 (reference) 1⋅00 (reference)
20–34 1510 0⋅95 (0⋅81, 1⋅12) 0⋅563 0⋅95 (0⋅80, 1⋅14) 0⋅615
35–54 764 1⋅01 (0⋅83, 1⋅23) 0⋅892 1⋅04 (0⋅85, 1⋅28) 0⋅691
≥55 478 0⋅98 (0⋅78, 1⋅23) 0⋅854 0⋅98 (0⋅77, 1⋅26) 0⋅897
Missing 526 0⋅65 (0⋅51, 0⋅83) <0⋅001 0⋅65 (0⋅50, 0⋅86) < 0⋅001
Bilobar disease 0⋅007 0⋅107
No 2423 1⋅00 (reference) 1⋅00 (reference)
Yes 2043 1⋅19 (1⋅05, 1⋅36) 1⋅16 (0⋅97, 1⋅39)
Missing† 44
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Table 4 Continued
Univariable analysis* Multivariable analysis*
No. of patients
(n = 4510) Odds ratio P Adjusted odds ratio P
Location of primary tumour 0⋅004 0⋅005
Colon 2908 1⋅00 (reference) 1⋅00 (reference)
Rectal 1596 1⋅22 (1⋅06, 1⋅39) 1⋅23 (1⋅06, 1⋅42)
Missing† 6
Nodal status of primary tumour 0⋅047 0⋅016
pN0 1246 1⋅00 (reference) 1⋅00 (reference)
pN1 1194 0⋅99 (0⋅83, 1⋅18) 0⋅837 0⋅93 (0⋅77, 1⋅12) 0⋅430
pN2 861 1⋅08 (0⋅89, 1⋅31) 0⋅421 1⋅04 (0⋅86, 1⋅27) 0⋅675
Missing 1209 0⋅83 (0⋅70, 0⋅99) 0⋅043 0⋅76 (0⋅63, 0⋅93) 0⋅006
Type of metastases 0⋅155
Metachronous 2362 1⋅00 (reference)
Synchronous 2103 0⋅91 (0⋅80, 1⋅04)
Missing† 45
Extrahepatic metastases 0⋅687
No 3823 1⋅00 (reference)
Yes 566 1⋅04 (0⋅86, 1⋅26)
Missing 121
Type of hospital 0⋅954
Regional 2490 1⋅00 (reference)
Tertiary referral centre§ 2020 1⋅00 (0⋅88, 1⋅14)
Values in parentheses are 95 per cent confidence intervals. *Multilevel logistic regression model with individuals nested for year of surgery. †Missing values
not included in analyses because of relatively small group. ‡Liver cirrhosis, oesophageal variceal disease, hepatorenal syndrome, liver failure, alcoholic liver
disease, toxic liver disease (mild), (chronic) hepatitis or liver fibrosis. §Defined as hospitals with highest expertise on oncological surgery.
variables to correct for confounding factors associated with
the use of the specific preoperative treatment modality.
Case-mix correction was performed using the
observed/expected (O/E) ratio, calculated by dividing
the observed number of patients who had a preoperative
imaging modality by the number of patients expected to
receive that modality. The expected number of patients
was based on a multivariable multilevel logistic regres-
sion model including case-mix variables, resulting in
case mix-corrected variability in the use of preoperative
imaging modalities between hospitals and oncological
networks. An O/E ratio of 1 was considered to indicate
that a hospital or oncological network performed exactly
the expected amount of preoperative imaging. When the
O/E ratio was below 1, a hospital or oncological network
performed less preoperative imaging than expected. If
the O/E ratio was higher than 1, a hospital or network
performed more preoperative imaging than expected. On
the basis of the model and O/E ratios for all hospitals or
oncological networks, 95 per cent confidence intervals
were calculated, indicating statistically significant outliers.
For all multivariable analyses, a two-step method was
undertaken. All variables were tested in a univariable model
per outcome variable. If a significant association was found
(P < 0⋅100, Wald test), the variable was entered in the mul-
tivariable model. Statistical significance was defined as a
two-sided P < 0⋅050 in the multivariable model. Outcomes
were adjusted odds ratios (ORs) and 95 per cent confidence
intervals. Multicollinearity was assessed in all multivariable
models. This was done by calculation of the variance infla-
tion factor (VIF). A VIF higher than 2⋅5 was considered to
indicate multicollinearity.
All analyses were performed in R version 3.2.2 (R Foun-
dation for Statistical Computing, Vienna, Austria).
Results
During the study inclusion period, 4846 patients under-
went surgical liver resection for CRLM. Of these, 336
patients were excluded because of missing information
on baseline characteristics, preoperative imaging tech-
niques, postoperative outcomes and postoperative onco-
logical classification. A total of 4510 patients were analysed,
of whom 1562 (34⋅6 per cent) had ceMRI, 872 (19⋅3 per
cent) had 18F-FDG PET–CT, and 1293 (28⋅7 per cent)
had both ceMRI and 18F-FDG PET–CT. The remaining
783 patients (17⋅4 per cent) did not receive any additional
imaging apart from CT.
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ceMRI or combined ceMRI and 18F-FDG PET–CT was
used more often in patients with a history of liver disease,
preoperative chemotherapy, synchronous metastases and
a rectal primary tumour. ceMRI was used less often in
patients with a greater maximum diameter of the largest
liver metastases. If more CRLM were present, ceMRI or
combined ceMRI and 18F-FDG PET–CT was used more
often. In patients with extrahepatic metastases 18F-FDG
PET–CT was used more often (Table 1).
Factors associated with use of different
preoperative imaging modalities
In multivariable multilevel logistic regression analysis, fac-
tors positively associated with preoperative use of ceMRI
included having an increasing number of CRLM (5 or more
tumours versus 1 tumour: adjusted odds ratio (OR) 2⋅45,
95 per cent c.i. 1⋅89 to 3⋅17; P < 0⋅001), a rectal primary
tumour (adjusted OR 1⋅44, 1⋅25 to 1⋅67; P < 0⋅001) and
synchronous metastases (adjusted OR 1⋅22, 1⋅05 to 1⋅41;
P = 0⋅012) (Table 2). Factors negatively associated with pre-
operative use of ceMRI included high ASA grade (adjusted
OR 0⋅74, 0⋅62 to 0⋅88; P = 0⋅001), history of liver resec-
tion (adjusted OR 0⋅79, 0⋅66 to 0⋅94; P = 0⋅006), max-
imum diameter of the largest CRLM (less than 20 mm
versus 55 mm or more: adjusted OR 0⋅32, 0⋅25 to 0⋅40;
P < 0⋅001), extrahepatic metastases (adjusted OR 0⋅74, 0⋅60
to 0⋅90; P = 0⋅003) and treatment in a tertiary referral cen-
tre (adjusted OR 0⋅79, 0⋅66 to 0⋅89; P < 0⋅001) (Table 2).
In multivariable multilevel logistic regression analy-
sis, factors positively associated with preoperative use of
18F-FDG PET–CT included higher CCI score (adjusted
OR 1⋅22, 95 per cent c.i. 1⋅05 to 1⋅40; P = 0⋅003), maxi-
mum diameter of largest CRLM (less than 20 mm versus
55 mm or more: adjusted OR 1⋅29, 1⋅03 to 1⋅62; P = 0⋅027)
and extrahepatic metastases (adjusted OR 1⋅45, 1⋅20 to
1⋅75; P < 0⋅001) (Table 3). Factors negatively associated
with preoperative use of 18F-FDG PET CT included only
synchronous metastases (adjusted OR 0⋅66, 0⋅58 to 0⋅76;
P < 0⋅001) (Table 3).
In multivariable multilevel logistic regression analysis,
the only factor associated positively with preoperative use
of a combination of ceMRI and 18F-FDG PET–CT was
rectal primary tumour (adjusted OR 1⋅23, 95 per cent c.i.
1⋅06 to 1⋅42; P = 0⋅005) (Table 4). There were no factors
associated negatively with the combined use of ceMRI and
18F-FDG PET–CT.
Trends in use of different imaging modalities over
the years
In the Netherlands, an increase was observed in the
preoperative use of ceMRI, from 9⋅6 per cent in 2014
Fig. 1 Case mix-corrected trend analysis using multivariable
logistic regression for the use of pretreatment imaging


















ceMRI + 18F-FDG PET–CT
Adjusted odds ratios (ORs) are shown with 95 per cent confidence
intervals. Case-mix variables for contrast-enhanced (ce) MRI were age,
Charlson Co-morbidity Index (CCI) score, BMI, ASA grade, history of
liver resection, number of colorectal liver metastases (CRLM), maximum
diameter of largest CRLM, location of primary tumour, type of metas-
tases, extrahepatic metastases and type of hospital. Case-mix variables for
[18F]fluorodeoxyglucose (18F-FDG) PET–CT were CCI score, preop-
erative chemotherapy, number of CRLM, maximum diameter of largest
CRLM, bilobar disease, location of primary tumour, nodal status of pri-
mary tumour, extrahepatic metastases and type of hospital. Case-mix vari-
ables for ceMRI and 18F-FDG PET–CT were ASA grade, BMI, history
of liver disease, history of liver resection, number of CRLM, maximum
diameter of largest CRLM, bilobar disease, location of primary tumour
and nodal status of primary tumour.
to 26⋅2 per cent in 2018. Univariable and multivariable
logistic regression for trend over the years showed that
this increase was statistically significant (adjusted OR 4⋅72,
95 per cent c.i. 3⋅69 to 6⋅05; P < 0⋅001) (Fig. 1; Table S1,
supporting information).
The use of preoperative 18F-FDG PET–CT between
2014 and 2016 was stable at around 25 per cent, but
use decreased in 2017 (14⋅7 per cent) and 2018 (6⋅0 per
cent). Univariable and multivariable logistic regression for
trend over the years showed that the decreasing trend
was statistically significant (adjusted OR 0⋅42, 95 per cent
c.i. 0⋅29 to 0⋅54; P < 0⋅001) (Fig. 1; Table S2, supporting
information).
The use of combined preoperative ceMRI and 18F-FDG
PET–CT was 15⋅0 per cent in 2014. During 2015 to 2017
this increased to 24⋅6 per cent, but was only 16.9 per cent in
2018. Univariable and multivariable logistic regression for
trend over the years showed concordant results regarding
the use of combined preoperative ceMRI and 18F-FDG
PET–CT (Fig. 1; Table S3, supporting information).
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Fig. 2 Unadjusted rates of hospital variation and case mix-corrected funnel plots of between-hospital and oncological network variation





































a  Unadjusted hospital variation in MRI use




a Unadjusted rates of between-hospital variation in use of contrast-enhanced (ce) MRI. b Funnel plot of between-hospital variation, case mix-corrected
for age, Charlson Co-morbidity Index (CCI) score, BMI, ASA grade, history of liver resection, number of colorectal liver metastases (CRLM), maximum
diameter of largest CRLM, location of primary tumour, type of metastases, extrahepatic metastases and type of hospital. c Funnel plot of oncological
network variation, case mix-corrected for age, CCI score, BMI, ASA grade, history of liver resection, number of CRLM, maximum diameter of largest
CRLM, location of primary tumour, type of metastases, extrahepatic metastases and type of hospital. O/E, observed/expected.
Variation in use of different imaging modalities
Variation between hospitals and oncological networks
was present for all preoperative imaging modalities. After
case-mix correction, significant hospital and oncological
network variation was still present.
Unadjusted rates for the proportion of patients with
CRLM receiving ceMRI in Dutch hospitals ranged
between 15.4 and 96.2 per cent (Fig. 2a). After case-mix
correction, widespread variation was observed in the use
of ceMRI in the Netherlands. Seven hospitals performed
more and eight hospitals performed less preoperative
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Fig. 3 Unadjusted rates of hospital variation and case mix-corrected funnel plots of between-hospital and oncological network variation






































b  Funnel plot of hospital variation in PET–CT use c  Funnel plot of network variation in PET–CT use











a Unadjusted rates of between-hospital variation in use of [18F]fluorodeoxyglucose (18F-FGD) PET–CT. b Funnel plot of between-hospital variation,
case mix-corrected for Charlson Co-morbidity Index (CCI) score, preoperative chemotherapy, number of colorectal liver metastases (CRLM), maximum
diameter of largest CRLM, bilobar disease, location of primary tumour, nodal status of primary tumour, extrahepatic metastases and type of hospital.
c Funnel plot of oncological network variation, case mix-corrected for CCI score, preoperative chemotherapy, number of CRLM, maximum diameter
of largest CRLM, bilobar disease, location of primary tumour, nodal status of primary tumour, extrahepatic metastases and type of hospital. O/E,
observed/expected.
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Fig. 4 Unadjusted rates of hospital variation and case mix-corrected funnel plots of between-hospital and oncological network variation
in the preoperative use of combined contrast-enhanced MRI and [18F]fluorodeoxyglucose PET–CT in patients with colorectal liver









































b  Funnel plot of hospital variation in combined MRI and
      PET–CT use
c  Funnel plot of network variation in combined MRI and
      PET–CT use











a Unadjusted rates of between-hospital variation in use of combined contrast-enhanced (ce) MRI and [18F]fluorodeoxyglucose (18F-FGD) PET–CT. b
Funnel plot of between-hospital variation, case mix-corrected for ASA grade, BMI, history of liver disease, history of liver resection, number of colorectal
liver metastases (CRLM), maximum diameter of CRLM, bilobar disease, location of primary tumour and nodal status of primary tumour. c Funnel plot
of oncological network variation, case mix-corrected for ASA grade, BMI, history of liver disease, history of liver resection, number of CRLM, maximum
diameter of largest CRLM, bilobar disease, location of primary tumour and nodal status of primary tumour. O/E, observed/expected.
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ceMRI than expected based on their case mix (Fig. 2b).
O/E ratios concerning the use of ceMRI between hospitals
ranged from 0⋅21 to 1⋅51. In addition, two oncological net-
works performed more preoperative ceMRI than expected,
whereas two other networks performed less preoperative
ceMRI than expected, with O/E ratios ranging between
0⋅75 and 1⋅23 (Fig. 2c).
Unadjusted rates for the proportion of patients with
CRLM receiving 18F-FDG PET–CT in Dutch hospitals
ranged from 10.0 to 100 per cent (Fig. 3a). After case-mix
correction, widespread variation in the use of 18F-FDG
PET–CT in the Netherlands was observed, with nine
hospitals performing more and ten hospitals performing
less preoperative 18F-FDG PET–CT than expected based
on their case mix (Fig. 3b). O/E ratios concerning the use
of 18F-FDG PET–CT between hospitals ranged from 0⋅24
to 2⋅20. In addition, three oncological networks performed
more preoperative 18F-FDG PET–CT than expected and
three other networks performed less than expected, with
O/E ratios ranging between 0⋅50 and 1⋅67 (Fig. 3c).
Unadjusted rates for the proportion of patients with
CRLM receiving combined ceMRI and 18F-FDG
PET–CT in Dutch hospitals ranged between 5.6 and 94.9
per cent (Fig. 4a). After case-mix correction, widespread
variation in the use of these combined imaging modalities
was found. Eight hospitals performed preoperative ceMRI
and 18F-FDG PET–CT more often and 11 hospitals
performed the combined imaging less often than expected
based on their case mix (Fig. 4b). O/E ratios for the use of
ceMRI and 18F-FDG PET–CT between hospitals ranged
from 0⋅19 to 3⋅25. In addition, two oncological networks
performed preoperative ceMRI and 18F-FDG PET–CT
more often than expected, whereas three other networks
performed the combined imaging less often than expected,
with O/E ratios ranging between 0⋅29 and 2⋅12 (Fig. 4c).
Multicollinearity was not observed for any of the
reported models in this study: the VIF was always below
2⋅0. Sensitivity analyses, in which tumour characteristics
were dropped from the analyses, did not show differences
in any of the outcomes.
Discussion
In this nationwide population-based analysis, ceMRI as
preoperative imaging for CRLM was used increasingly in
the Netherlands over time, whereas the use of 18F-FDG
PET–CT decreased. The use of combined ceMRI and
18F-FDG PET–CT remained stable over the years. Use
of MRI was associated with smaller diameter of CRLM
or more CRLM. Use of 18F-FDG PET–CT was asso-
ciated with extrahepatic metastases and larger diameters
of CRLM. Notable variation was present regarding the
use of preoperative ceMRI, 18F-FDG PET–CT, and com-
bined ceMRI and 18F-FDG PET–CT between hospitals
and oncological networks in the Netherlands.
Few studies on trends and variation in the use of pre-
operative imaging have been published in the past. One
French study29 showed that use of preoperative liver
ceMRI increased from 53 to 80 per cent between 2009 and
2013, and 72 per cent of patients with resectable CRLM
had preoperative ceMRI. In a Swedish population-based
study30, only 2 per cent of all patients with colorectal
cancer had preoperative ceMRI of the liver. Unfortunately,
this study did not report on trends or report a subanalysis
of patients with CRLM.
The available evidence is not conclusive regarding the use
of additional preoperative imaging modalities, resulting in
variability in the use of ceMRI and 18F-FDG PET–CT.
Over the past few years, several studies8,10,11 have reported
superior per lesion detection with MRI compared with
conventional CT in patients with CRLM. An earlier report
by Rojas Llimpe and colleagues31 provided insight into the
additional value of ceMRI in patients receiving preopera-
tive chemotherapy. Mostly retrospective studies have been
performed to assess differences between different types of
MRI, such as ceMRI, diffusion-weighted MRI or gadox-
etic acid-enhanced liver MRI. New insights into the added
value of different types of MRI in a prospective setting are
needed. For this reason, the multicentre CAMINO trial
(https://www.trialregister.nl/trial/8039): Netherlands Trial
Register number NL8039 was commenced in the Nether-
lands in 2019; this trial aims to provide information con-
cerning the clinical additional value of ceMRI in patients
with CRLM.
18F-FDG PET–CT is thought to have lower sensi-
tivity than ceMRI, and is not favoured in the detection
of CRLM4,32. Detection rates are lower in patients who
have received preoperative chemotherapy32. One RCT12
investigated the additional value of 18F-FDG PET–CT in
CRLM and concluded that this did not influence survival,
whereas several unrandomized studies15,33,34 indicated that
there could be added value for 18F-FDG PET–CT in
patients with extrahepatic metastases.
Large randomized trials or prospective multicentre stud-
ies on the use of ceMRI or 18F-FDG PET–CT in patients
with CRLM have not been conducted, and thus exist-
ing guidelines (such as the Dutch guideline) do not pro-
vide recommendations on what is needed. The Dutch
guideline does not favour either ceMRI or CT in the
work-up before liver resection. It advises using 18F-FDG
PET–CT only in patients with extrahepatic metastases22.
In the present study, an increase in the use of ceMRI in
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the Netherlands was observed, whereas use of 18F-FDG
PET–CT decreased. These trends are probably the result
of international publications4,7,8,10,12,13,15,31,34 reporting the
additional value of these imaging modalities.
Interestingly, ceMRI is thought to provide better insight
into tumour burden in patients with a medical history of
liver disease, and the literature10,32 indicates that ceMRI
could be useful as preoperative imaging in patients under-
going preoperative chemotherapy or who have had previ-
ous liver resection. 18F-FDG PET–CT might have added
value in patients with a higher nodal status of the colo-
rectal primary tumour. However, this was not the case
in the present study, as these factors were not associated
with the use of either of the imaging modalities in this
population-based cohort. In addition, ceMRI was used less
often in tertiary referral centres, whereas there was no dif-
ference in the use of 18F-FDG PET–CT in the different
types of hospital.
Variation in the use of imaging in the Netherlands could
be explained by the fact that the Dutch guideline allows dif-
ferent approaches35. Notable variation in imaging at both a
hospital and oncological network level reflects lack of con-
sensus on both levels. There are several possible reasons
for this. First, there is insufficient evidence and guidelines
concerning the use of preoperative imaging in patients with
CRLM. Second, health economic discussions could influ-
ence the use of these imaging modalities, as ceMRI and
18F-FDG PET–CT are both more expensive than base-
line ultrasonography and CT36. As there are considerable
differences in the costs of the various imaging modali-
ties, it is important to acknowledge these and to assess the
cost-effectiveness of imaging modalities for CRLM in the
future.
Hospital variation is undesirable from a national
healthcare perspective. Either unnecessary imaging was
performed or different approaches to imaging led to
different patient selection for treatment. It would be inter-
esting to explore whether these differences in preoperative
imaging lead to differences in treatment selection, and
in disease-free and overall survival. A next step in the
audit is to incorporate long-term follow-up to investigate
these associations further, to ensure that conclusions can be
drawn concerning survival data. The authors advocate clear
evidence-based guidelines regarding preoperative imaging
for CRLM. This study and the upcoming CAMINO trial
can be used to revise the Dutch, and maybe international,
guidelines.
The present study has several limitations. First, the
disadvantage of the audit data may be accuracy, design
and selection of patients. Details including information
on the timing of registration of tumour characteristics,
multidisciplinary meetings and outcomes of these meetings
were missing and could not be retrieved in this retrospec-
tive study. The denominator (the sum of patients treated
surgically and those treated otherwise) was unclear. Sec-
ond, it is not mandatory to register open-and-close proce-
dures in the DHBA. This makes it difficult to evaluate the
impact of the use of preoperative imaging on perioperative
outcomes.
The strength of the study is the nationwide collection
of data through mandatory participation of all Dutch hos-
pitals performing liver surgery. Because of the nationwide
coverage, the results reflect daily clinical practice. It is pos-
sible to reflect on how Dutch clinicians use preoperative
imaging and to evaluate hospital and oncological network
variation.
Trends over the years show increasing use of ceMRI and
decreasing use of 18F-FDG PET–CT for CRLM in the
Netherlands. The lack of specific guidelines on preopera-
tive imaging encourages hospital and oncological network
variation in the use of ceMRI, 18F-FDG PET–CT, and
combined ceMRI and 18F-FDG PET–CT. Convincing
evidence concerning effective preoperative imaging modal-
ities for CRLM is needed to decrease nationwide variation.
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